A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells

Diwakar Bastihalli Tukaramrao 1,†, Saloni Malla 1,†, Siddharth Saraiya 2, Ross Allen Hanely 1, Aniruddha Ray 3, Shikha Kumari 1, Dayanidhi Raman 4 and Amit K. Tiwari 1,*

1 Department of Pharmacology and Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, University of Toledo, Toledo, OH 43614, USA; diwakarbt02@gmail.com (D.B.T.); saloni.malla@rockets.utoledo.edu (S.M.); ross.hanely@utoledo.edu (R.A.H.); shikha.pharma08@gmail.com (S.K.)
2 Department of Radiation Oncology, College of Medicine, University of Toledo, Toledo, OH 43614, USA; saraiya.s@gmail.com
3 Department of Physics, College of Natural Sciences, University of Toledo, Toledo, OH 43614, USA; aniruddha.ray@utoledo.edu
4 Department of Cancer Biology, College of Medicine, University of Toledo, Toledo, OH 43614, USA; dayanidhi.raman@utoledo.edu
* Correspondence: amit.tiwari@utoledo.edu; Tel.: +1-4193831913
† Equal contributions.

Simple Summary: Triple-negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer that lacks an estrogen receptor, the progesterone receptor and the human epidermal receptor, making it unsuitable for hormonal-based therapy. TNBC is known for its higher relapse rate, poorer prognosis and higher rate of metastasis compared to non-TNBC because although patients initially respond to chemotherapy that kills cancer cells through a form of programmed cell death called apoptosis, they later develop chemoresistance and stop responding to the treatment, accounting for one fourth of all breast cancer deaths. In this study, we report a novel compound, TPH104, that elicits a unique, non-apoptotic cell death in TNBC cells. Upon treatment with TPH104, TNBC cells swell and burst, releasing immunogenic markers that alert and activate the immune system to further recognize and attack the neighboring breast cancer cells.

Abstract: Enhancing the tumor immunogenic microenvironment has been suggested to circumvent triple-negative breast cancer (TNBC) resistance and increase the efficacy of conventional chemotherapy. Here, we report a novel chemotherapeutic compound, TPH104, which induces immunogenic cell death in the TNBC cell line MDA-MB-231, by increasing the stimulatory capacity of dendritic cells (DCs), with an IC50 value of 140 nM. TPH104 (5 µM) significantly increased ATP levels in the supernatant and mobilized intracellular calreticulin to the plasma membrane in MDA-MB-231 cells, compared to cells incubated with the vehicle. Incubating MDA-MB-231 cells for 12 h with TPH104 (1–5 µM) significantly increased TNFα mRNA levels. The supernatants of dying MDA-MB-231 cells incubated with TPH104 increased mouse bone marrow-derived DC maturation, the expression of MHCI and CD86 and the mRNA expression of TNFα, IL6 and IL12. Overall, these results indicate that TPH104 induces immunogenic cell death in TNBC cells, in part, by activating DCs.

Keywords: triple-negative breast cancer; thienopyrimidine analog; immunogenic cell death; non-apoptotic cell death; dendritic cells; TNF-α
1. Introduction

The activation of the immune system in cancer plays a critical role in determining the long-term success of anticancer therapies [1–6]. The induction of immunogenic cell death (ICD) by cancer chemotherapy can activate the immune system to target cancer [1,4,7]. ICD is characterized by an alteration in the levels of calreticulin (CRT) in the plasma membrane of cancer cells [7] and the release of damage-associated molecular pattern (DAMP) molecules, such as ATP and high mobility group B1 (HMGB1), from dying cancer cells [1,8]. DAMPs activate dendritic cells (DCs), leading to the cross-presentation of tumor antigens to cytotoxic T lymphocytes (CTL) that mediates the tumor-specific immune response [7,9,10]. DCs play a critical role in shaping the antitumor immune response at the interface of the innate and adaptive immune systems [11]. Frequently, cancer cells are not recognized by sentinel immune cells (immune cloaking) or they become quiescent or anergic through co-opting of the immune cells, thus evading the immune response. This immunoediting allows tumor cells to survive, proliferate and metastasize to distant sites [12]. Therefore, augmenting the DC response using \textit{ex vivo} DC-based vaccination approaches [13] or activating DCs in the tumor microenvironment (TME) by chemotherapeutic drugs (e.g., anthracyclines, cyclophosphamide and oxaliplatin) is important. The induction of ICD may become more effective approach in cancer immunotherapy [4,8,14].

The efficacy of chemotherapeutic drugs to increase tumor cell death by immune activation is primarily attributed to the rapid translocation of preformed intracellular CRT to the outer leaflet of the plasma membrane (PM) of the tumor cells [7,14]. The translocated CRT can be a ligand for phagocytic receptors or adaptor proteins known to interact with CRT in the lipid rafts of the PM [15] that facilitate the DC uptake of fragments from dying cells [15,16]. Currently, studies have demonstrated that the translocation of CRT to the PM requires signaling events that activate endoplasmic reticulum (ER) stress, apoptosis and a terminal translocation module to expose CRT on the cell surface [14,17]. Other important biochemical events associated with ICD include the active release of ATP and HMGB1 to the extracellular milieu [8]. ATP induces the recruitment of antigen-presenting cells (APC), including dendritic cells at the tumor site, by activating the purinergic receptors P2RX7 and P2RY2 [18]. Although the underlying mechanism of HMGB1 release from cells undergoing ICD remains to be elucidated, it has been shown that HMGB1 mediates significant adjuvant-like effects by binding to various pattern recognition receptors, such as Toll-like receptors 2 and 4 (TLR2 and TLR4) and receptors for advanced glycosylation end products (AGE) [19]. These ICD-associated DAMPs recruit APCs to the tumor site and increase their capacity to engulf, process and cross-present tumor-derived antigens to T cells. This favors the induction of tumor-specific adaptive immunity.

Tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLSs) have favorable prognostic value in TNBC [20]. The immune response in tumors is mainly dependent on adaptive immunity mediated by T cells [21]. CD8+ T cells evolve and kill tumor cells by releasing perforin, granzymes and INF-γ [22]. DCs are central to the initiation of primary immune responses and they are the only antigen-presenting cells capable of stimulating T cells, making them pivotal in the generation of adaptive immunity [23]. TNBC patients with higher levels of TILs and TLSs in the TME have better clinical outcomes [24,25]. Additionally, recent reports suggest that CD11C+ dendritic cells have a strong correlation with the levels of TILs and TLSs in TNBC [26]. Therefore, therapeutic modalities that facilitate activation and recruitment of CD11C+ DCs has immense value. In addition, CD11C is a type I transmembrane protein that is expressed on monocytes, granulocytes, a subset of B cells, DCs and macrophages. Highly enriched CD11C+ DCs can be isolated from mouse bone marrow [27] to assess their activation or maturation status by various agents \textit{ex vivo}.

TNF-α activates TNF receptors and induces either cellular proliferation, survival, differentiation or cell death, depending on the contextual presence of other signaling molecules [28]. Approximately 28% of all cancers have been shown to be susceptible to direct killing by TNF-α [29]. The antitumor activity of TNF-α is mediated by the cell surface
receptor TNFR1 which activates caspase-8, culminating in apoptosis [28]. An important downstream regulator of TNFR signals is the enzyme called receptor interaction protein kinase 1 (RIPK1) [28]. The type of ubiquitination mark on RIPK1 determines whether a cell undergoes proliferation or death [30]. It is well known that TNBC can become resistant to various chemotherapeutic drugs, including anthracycline-based compounds [31,32]. Therefore, activating TNFR with TNF-α, in combination with pan caspase inhibitors, such as z-VAD-FMK, to induce cell death by necroptosis, could represent a therapeutic approach in treating TNBC [33]. Indeed, it has been reported that MDA-MB-231 TNBC cells, when incubated with small-molecule antagonists of inhibitors of apoptosis (IAPs), also known as second mitochondria-derived activator of caspases (SMAC) mimetics, activate the autocrine production of TNF-α by activating RIPK1 [34]. In addition, several studies in different types of cancers have shown the potential of ICD inducers to increase the levels of pro-inflammatory cytokines, including TNF-α, to produce an immunogenic TME [3,35–40]. Although TNF-α is known to cause systemic inflammation [28], the selective and restricted activation of the TNF-α pathway in cancer cells, if achieved, could reprogram DCs in the TME to target cancer cells.

In the present in vitro study, we report that a novel small, thienopyrimidine-derived molecule, TPH104, produces a non-apoptotic cell death in TNBC cells [41]. MDA-MB-231 cells were highly sensitive to TPH104, while noncancerous cells were relatively resistant to TPH104. Unlike most small molecules, TPH104 induced rapid membrane permeabilization and had characteristics of non-apoptotic cancer cell death in culture. In addition, TPH104 induced ATP release, increased the cell surface translocation of CRT and activated the endogenous TNF-α pathway by imparting immunogenic characteristics to dying MDA-MB-231 cells. Furthermore, the contents released by such dying tumor cells stimulated the maturation of DCs and upregulated the inflammatory gene expression. These effects of TPH104 in TNBC cells activate DCs and suggest that TPH104 may represent a novel therapeutic candidate in the treatment of aggressive breast cancers.

2. Materials and Methods

2.1. Chemicals, Antibodies and Reagents

Recombinant mouse (rm) GM-CSF (#BMS325), 2-mercaptoethanol (# 21985-023) and a high-capacity cDNA reverse transcription kit (# 4368814) were obtained from Life Technologies (Grand Island, NY). FITC anti-mouse MHC class II antibody (#11-5321-81) and calreticulin antibody (# PA3-900) were obtained from Thermo Fisher Scientific, Inc. (Waltham, MA). Human TNF-α neutralizing antibody (#7321S), anti-rabbit IgG (H+L) Fab2-Alexa Flour 488 (#4412), Immunofluorescence blocking buffer (#12411P), Immunofluorescence antibody dilution buffer (#12378P) and 16% formaldehyde (#12606P) were obtained from Cell Signaling Technology (Danvers, MA, USA). A human TNF-α ELISA kit (#43204), Tru Stain fcX (anti-mouse CD16/32), Clone: 93 (#101320), PE/Cy7 anti-mouse CD86 antibody, Clone: GL-1 (#105013), and APC anti-mouse CD11c- antibody, Clone: N418 (#117310), were obtained from BioLegend. Lipopolysaccharide (LPS) (Escherichia coli serotype 0111: B4) (# L4391), necrostatin-1 (# N9037), ATP (# A7699) and doxorubicin hydrochloride (# D1515) were purchased from Sigma (St. Louis, MO). TPH104 was synthesized in-house, and the synthetic scheme and its characterization will be published elsewhere. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (# T-030-10) was obtained from Gold Biotechnology (St. Louis, MO). Mitoxantrone (# S2485) was obtained from Selleck Chemicals (Houston, TX, USA). SYBR Green supermix (# 95054) was obtained from QuantaBio (Beverly, MA). Fluoroshield mounting medium with 4’,6-diamidino-2-phenylindole (DAPI, # ab104139) was obtained from Abcam (Cambridge, MA). A bicinchoninic acid assay (BCA) protein quantitation kit (# 786-570) was obtained from G-Biosciences (St. Louis, MO). SP600125 (#10010466), a potent and reversible inhibitor of c-Jun N-terminal kinase (JNK), was obtained from Cayman chemicals, Ann Arbor, MI.
2.2. Cell Culture

MDA-MB-231 and BT-20 cell lines were obtained from the late Dr. Gary Kruh (University of Chicago, Illinois). Human primary epithelial gingival keratinocytes (HPK), and normal colon fibroblast CRL1459 cells were purchased from American Type Culture Collection (ATCC®PCS-200-014, and ATCC®CCD-18Co – CRL-1459, respectively, Manassas, VA). These cells were grown as an adherent monolayer with Dulbecco’s Modified Eagle’s Medium (Corning, Tewksbury, MA) supplemented with 10% fetal bovine serum (Biofluids Technologies, Port Richey, FL), 2 mM of L-glutamine and 100 U/mL of penicillin and 100 µg/mL of streptomycin (Thermo Fisher Scientific, Inc., Waltham, MA), as previously described [42]. HPKs cells were cultured in dermal cell basal medium (ATCC® PCS-200-030) supplemented with factors from Keratinocyte growth kit (ATCC® PCS-200-040) as per manufacture’s protocol. These cells were cultured in a humidified incubator containing 5% CO2 at 37°C. All cells were assessed and confirmed to be free of fungi and mycoplasma. Cells were obtained from frozen stocks and cell passaging (up to P4) was performed at 80% cell confluence trypsin + 2.2 mM EDTA in phosphate buffered saline (PBS).

2.3. Cell Cytotoxicity Assay

The MTT assay was performed to determine the cytotoxic efficacy of TPH104, as described previously [43]. Briefly, in a 96-well flat-bottom cell culture plate, cells were seeded at a density of 3×10³ cells/well (in 100 µL) and incubated overnight. The next day, cells were incubated with TPH104 in 100 µL to achieve a final concentration of 0.05, 0.1, 0.25, 0.5, 1, 5, 10, 25 or 50 µM in a total volume of 200 µL. After 72 h of incubation, 20 µl of 4 mg/mL of MTT was added to the plate and incubated for 3 h at 37°C. Following incubation, the supernatant was removed, and the insoluble formazan precipitates were solubilized in 150 µL of dimethyl sulfoxide (DMSO) and mixed on a plate shaker for 10 min. The absorbance was measured with a micro-plate reader (Synergy H1, Biotek, Vermont, USA) at 560 nm. IC50 values were calculated from the nonlinear regression curve fit of log of inhibitor versus the dose response parameter in the GraphPad Prism (Version 8.4.3, GraphPad Software, San Diego, CA) program.

2.4. IncuCyte™ Live-Cell Morphology Study

The morphological changes induced by TPH104 on MDA-MB-231 cells were visualized through the Incucyte® S3 Live-Cell Analysis System (Ann Arbor, MI, USA). Briefly, MDA-MB-231 cells were seeded at 4000 cells/well in a 96-well plate and incubated overnight in a 37°C, 5% CO2 incubator. Then, the cells were treated with varying concentrations (0, 0.5, 1 and 5 µM) of TPH104 and placed in the Incucyte system. The images were then captured at different time points using the integrated IncuCyte S3 software version 2020B.

2.5. Preparation of the Conditioned Media (CM) from Death-Primed MDA-MB-231 Cells

The MDA-MB-231 cells were cultured in 60 mm culture dishes in the presence of vehicle (<0.1% DMSO), TPH104 (1 or 5 µM), MX (1 µM) and DOX (1 µM). The supernatants were collected after 0, 24 and 48 h of incubation and ATP levels in the supernatants were measured using CellTiter-Glo® kits (Promega, Madison, WI). The supernatants collected were concentrated by centrifugation in 10,000 MWCO (molecular weight cutoff) centrifuge tubes (Millipore Sigma, Burlington, MA) at 3000g for 30 min at 4°C and stored at -80°C. VC-CM represents the vehicle control (VC) conditioned media (CM) of MDA-MB-231 cells incubated with vehicle, whereas TPH104-1-CM describes the CM of MDA-MB-231 cells incubated with TPH104 (1 µM); TPH104-5-CM, the CM of MDA-MB-231 cells incubated with TPH104 (5 µM); MX-1-CM, the CM of MDA-MB-231 cells incubated with mitoxantrone (1 µM); and DOX-1-CM, the CM of MDA-MB-231 cells incubated with doxorubicin (1 µM). A schematic representation of the protocol is provided in Figure S1.
2.6. The Generation of Mouse Bone Marrow-Derived Dendritic Cells (BMDCs)

Mouse bone marrow-derived dendritic cells (BMDCs) were generated as previously described [44], with minor modifications. Briefly, mouse BM cells were removed from the femurs of sacrificed C57BL/6 mice and depleted of erythrocytes by hypotonic lysis using 0.8% ammonium chloride. BM cells were cultured in RPMI-1640 (Life Technologies, Grand Island, NY), supplemented with 5% heat-inactivated fetal bovine serum (# BT-101-500-D; Biofluid Technologies LLC, Florida, USA), L-glutamine (0.03%), sodium pyruvate (0.4 mM), 2-mercaptoethanol (50 mM), mGM-CSF (20 ng/mL) and penicillin/streptomycin in 60 mm culture dishes (2.5×10^6 cells/dish). Fresh culture medium was replaced on days 3 and 5. On day 6, loosely held, non-adherent cells were harvested and reseeded at a density of 1.5×10^6 cells per well in a 6-well plate, incubated with conditioned media harvested from death-primed MDA-MB-231 cells, in a ratio of 1:7.5 and cultured for 24 h before harvest, were used for flow cytometry or PCR assays. LPS was used as a positive control for stimulation of DCs.

The BM cells were generated from the femurs of male C57BL/6 age-matched mice, purchased from Taconic Biosciences, Inc. (Hudson, NY, USA) and maintained on an AIN-76-based semi-purified diet from Harlan-Teklad (Madison, WI, USA). The animal protocols in this study were approved by the Institutional Animal Care and Use Committee and the Institutional Biosafety Committee at the University of Toledo.

2.7. Flow Cytometry

Cells were counted after trypan blue staining using a hemocytometer. Approximately 5×10^5 cells were suspended in 100 µL of flow buffer (phosphate-buffered saline (GE Life Sciences), containing 100 IU/mL of penicillin (Corning), 100 µg/mL of streptomycin (Corning) and 2% (v/v) fetal bovine serum (Biofluid Technologies). The staining of the extracellular cell surface antigens was performed by incubating cells with 0.25 µg of Fc block (Tru Stain fcX; BioLegend) for 10 min, followed by 30 min of incubation at 4°C, with the following antibodies: 0.125 µg of FITC-conjugated MHCII (Invitrogen), 1 µg of PE-Cy7-conjugated CD86 (BioLegend) and 0.25 µg of APC-conjugated CD11c+ (BioLegend). Subsequently, the cells were washed with flow buffer and collected on a BD Accuri C6 plus Flow Cytometer (BD Biosciences), including unstained and single-stained controls. Single cells were obtained by gating on FSC-A versus FSC-H, followed by SSC-A versus APC-A. APC-CD11c+ gated cells were further resolved into distinct Hi and Lo populations of CD86 and MHCII. The data analysis was performed using FlowJo (Ashland, OR) software.

2.8. Extracellular ATP Release Measurements

Cells were incubated at 37°C with Opti-MEM (Life Technology) containing vehicle or the test compounds. Supernatants were collected at 48 h and ATP levels were measured using the CellTiter-Glo ATP assay system kit (Promega, Madison, WI, USA). ATP levels were calculated based on an ATP standard curve.

2.9. Measurement of TNF-α

The MDA-MB-231 cells were seeded at a density of 6.0×10^5 cells in 6 cm culture dishes (Falcon). The cells were cultured overnight and the following day, culture media were replaced with 2.85 mL of fresh media containing either vehicle (<0.1% DMSO) or 50 µM Nec-1 for 45–60 min. Subsequently, the cells were incubated with either vehicle or TPH104, at a final concentration of 1 or 5 µM, for 48 h and the supernatant and cells were collected and stored at −80°C. TNF-α levels were measured using an ELISA kit (BioLegend, San Diego, CA) according to the manufacturer’s instructions, and the values were normalized to the total cellular protein content.
2.10. RNA Extraction and Real-Time Quantitative PCR

Cells were harvested in 1 mL Tri Reagent (Thermo Fisher Scientific) after incubation with vehicle or the test compounds, following gentle washing with ice-cold PBS, and stored at −80°C until RNA extraction was performed. RNA extraction was conducted according to the manufacturer’s protocol, with modifications, as previously described [45]. Subsequently, RNA was reverse transcribed to cDNA using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies). cDNA from various cell samples was amplified with specific primers (human TNFα: 5'-GGTTCTTTGCTTGCTGCAA-3' and 5'-CTTGAAGCAATGCTGTC-3'; mouse TNFα: 5'-TCTCAAGCCTTAGCTGTC-3'; mouse IL1β: 5'-TTGACCAGCCCTGCTGCAA-3' and 5'-AGAAGGATGCTGCTGTC-3'; mouse IL6: 5'-ACACAGTGAGTCAGCT-3' and 5'-CTTGTGCCTAGCCCTATC-3'; mouse IL12A: 5'-CCTCGAGCCTGCTGTC-3' and 5'-AGTGTGAGGGTCTGGCT-3'; mouse IL12B: 5'-TGACACAGCCAGCAGAATA-3' and 5'-AAATGGTACGACAGAT-3'; human β-actin: 5'-CCTCTATGCCAACACAGCC-3' and 5'-ATGCACCAGTACCCCTATC-3') and the data were normalized to mouse β-actin: 5'-CCTCTATGCCAACACAGCC-3' and 5'-ATGCACCAGTACCCCTATC-3', and human β-actin: 5'-CCTCTATGCCAACACAGCC-3' and 5'-ATGCACCAGTACCCCTATC-3', in a CFX Connect Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Transcript abundance was analyzed, and 2-ΔΔCt was calculated to represent changes in gene expression relative to controls [46].

2.11. Immunofluorescence for Calreticulin

The MDA-MB-231 cells were seeded on 12.0 mm round sterile glass coverslips (1.5 × 10⁵ cells/well) in a 12-well plate. Cells were cultured overnight and incubated with either vehicle, TPH104 (5 µM for 6 h) or mitoxantrone (1 µM for 2 h). After incubation, cells were placed on ice, washed twice with PBS and fixed with 4.0% PFA in PBS for 5 min. Cells were then washed twice in PBS and blocked for 1 h with blocking buffer (Cell Signaling). Subsequently, a calreticulin polyclonal antibody (Invitrogen), diluted in antibody dilution buffer (1:100), was added for 1 h at room temperature. After washing three times in ice-cold PBS, the cells were incubated for 1 h with goat anti-rabbit IgG (Fab2) Alexa Flour 488 (Cell Signaling), diluted 1:1000 in cold antibody dilution buffer. The cells were washed three times with PBS, dried and mounted on slides with the mounting medium, including DAPI (Abcam), and allowed to cure overnight. Fluorescence microscopic assessment was performed using a Zeiss Axiovert 40 CFL inverted fluorescence microscope (Carl Zeiss, Germany). Fluorescence intensity was quantified using NIH image J software.

2.12. Statistical Analysis

Experiments were repeated at least three times or as indicated in the legends. Data are expressed as the mean ± SEM. Either an unpaired one-tailed t-test or unpaired two-tailed t-test was used and the results were analyzed using GraphPad Prism (GraphPad Software). The a priori significance level was p ≥ 0.05.

3. Results

3.1. Cytotoxicity of TPH104 is Selective to MDA-MB-231 Cells

In order to determine the IC₅₀ value of TPH104 for MBA-MB-231 and BT-20 cells, were incubated with various concentrations of TPH104 for 72 h and their viability was determined using the MTT assay. The IC₅₀ value of TPH104 (Figure 1A), on TNBC cells for MDA-MB-231 was 140 nM and BT-20 cells were 270 nm, respectively, while it was higher in the normal gingival epithelial HPKs (i.e., 15.23 μM) and normal colon fibroblast CRL-1459 (i.e., 24.7 μM (Figure 1B). This suggest that TPH104 has > 100-fold selectivity for normal cells compared to TNBC MDA-MB-231 cells.
Incubation with TPH104 (0.5, 1 and 5 µM) produced a concentration-dependent decrease in cell density (Figure 1C, D). TPH104 induced cellular swelling and an increase in the permeability of the MDA-MB-231 cell membrane (Figure 1E). In addition, the incubation of MDA-MB-231 cells with 10 µM of TPH104 produced large, stable and continuously expanding membrane blebs and swelling (Figure 1E) (Video S1) and plasma membrane permeabilization, indicative of necrotic cell death [47]. The occurrence of membrane hyperpermeability indicates decreased cell viability. Overall, our results indicate that TPH104 induced selective non-apoptotic type of cell death in MDA-MB-231 and BT-20 cells.
3.2. TPH104-Mediated Death Primes MDA-MB-231 Cells to Express Biomarkers of Immunogenicity

Chemotherapeutic compounds have been shown to induce ICD [9]. Important biomarkers of ICD include cell surface exposure of calreticulin by death-primed cells [7] and the release of ATP and HMGB1 as they undergo death [9]. To assess the effect of TPH104 on the immunogenic modulation of MDA-MB-231 cells, we measured ATP levels in the culture supernatant of the cells. MDA-MB-231 cells incubated with 5 µM of TPH104 for 24 or 48 h released a significantly higher amount of ATP into the culture supernatant compared to the vehicle control (Figure 2A). Furthermore, the expression of CRT was significantly increased in MDA-MB-231 cells incubated with TPH104 (5 µM) and mitoxantrone (MX—1 µM, positive control) compared to cells incubated with the vehicle (Figure 2B). At higher magnifications, the concentrated fluorescence of CRT in the plasma membrane microdomains was more prominent following the incubation of MDA-MB-231 cells with either TPH104 or MX compared to the control cells incubated with the vehicle (Figure S2). Our *in vitro* results suggest that TPH104 can increase the expression of immunogenic biomarkers in death-primed MDA-MB-231 cells.
Cancers 2021, 13, 1954

Figure 2. TPH104 upregulates biomarkers of immunogenic cell death in MDA-MB-231 cells. (A) The amount of ATP released into the extracellular medium after treatment with TPH104 for the indicated time was measured as described in Methods. *, p < 0.05; ****, p < 0.0001 compared to ATP levels in the extracellular space of MDA-MB-231 cells incubated with vehicle (< 0.1% DMSO), Student’s t test. n = 4 independent experiments. (B) Immunofluorescence detection of cell surface CRT (pseudo-colored in green, FITC) in MDA-MB-231 cells after treatment with either vehicle (media with <0.1% DMSO), TPH104 (5 µM; 6 h) or MX (1µM; 2h). The nuclei were visualized with DAPI (40×). A representative bar graph depicting the fluorescence intensity of Vehicle, TPH104 and MX is also shown. Data represent means ± SEM. *, p < 0.05, ***p < 0.001 by Student’s t test.

3.3. TPH104 Induces the Production of TNF-α by MDA-MB-231 Cells

MDA-MB-231 cells can produce TNF-α after the inhibition of cytoplasmic inhibitors of apoptosis in the RIP1 kinase-dependent pathway [34]. Given that our morphological studies indicated onco-necrosis, this led us to hypothesize that TPH104 may increase the levels of TNF-α in MDA-MB-231 cells. TPH104 (1 or 5 µM) significantly increased (p > 0.01) the levels of TNF-α mRNA, as determined by qPCR in MDA-MB-231 cells (Figure 3A). Compared to the control, the cells incubated with 1 µM of TPH104 for 24, 36 or 48 h produced a 48, 81 and 62% increase in TNF-α mRNA expression, respectively. This trend was also observed at higher concentrations of TPH104 (5 µM) which produced a 62, 112 and 108% increase in TNF-α mRNA levels at 24, 36 or 48 h, respectively, as compared to the control (Figure 3A). Furthermore, TPH104 (1 and 5 µM) significantly increased (p ≥ 0.0001) the level of the TNF-α protein to 16.7 and 77.1 pg/mg, respectively (basal levels of TNF-α were 0.26 pg/mg of total protein in MDA-MB-231 cells incubated with the vehicle) (Figure 3B). As the data suggest that TPH104 can activate the TNF-α pathway in MDA-MB-231 cells, we blocked TNF-α signaling with a TNF-α-neutralizing antibody (0.2, 1 and
5 µg/mL) in MDA-MB-231 cells incubated with 1, 5 or 10 µM of TPH104. There was no significant decrease in the TPH104-induced cytotoxic effects (Figure 3C). These results indicate that TPH104 activated the TNF-α pathway and TNFα does not mediate cell death in MDA-MB-231 cells.

Figure 3. TPH104 activated endogenous production of TNFα in dying MDA_MB-231 cells. (A) Real-time PCR of RNA isolated from MDA-MB-231 cells at the indicated time after treatment with either TPH104 or vehicle (media with <0.1% DMSO). Relative levels of the TNF-α transcript were determined compared with β-actin and the fold change was calculated by comparing with vehicle-treated cells. **, p < 0.01; ****, p < 0.0001 compared to vehicle-treated cells, Student’s t test. n = 3 independent experiments. (B) TNF-α levels determined by TNF-α ELISA and normalized to total protein in lysate from MDA-MD-231 cells treated with either vehicle or TPH104 (1 and 5 µM) for 48 h. Data shown are mean ± S.E.M, ****, p < 0.0001 compared to vehicle-treated cells, Student’s t test. n = 3 independent experiments. (C) ATP assay of total lysates of MDA-MB-231 cells treated with TPH104 (0, 1, 5 and 10 µM) ± TNFα-neutralizing antibody (0.2, 1, 5 µg/mL) after 48 h (the experiment was performed in technical triplicates).

3.4. TPH104 Elicits the Release of Factors from MDA-MB-231 Cells That Induce the Maturation of DCs

Dendritic cells respond to external stimulatory signals (PAMPs and DAMPS) and upregulate the surface expression of maturation markers such as MHCIi, CD86 and CD80 [48]. Such an activation of DCs by stimulatory signals including TNF-α increases CD8+ T cell-mediated antitumor immunity that is essential for the efficacy of cancer immunotherapy [49]. Since TPH104 induced the production of immunogenic biomarkers including
TNFα in MDA-MB-231 cells, it prompted us to investigate the effect of supernatants collected from MDA-MB-231 cells that were death primed by TPH104. Therefore, BMDCs were incubated ex vivo with a 7.5:1 ratio of BMDC media and conditioned media collected from either the vehicle (VC-CM)-, 1 µM TPH104 (TPH104-1CM)-, 5 µM TPH104 (TPH104-5-CM)- or 1 µM mitoxantrone (MX-1-CM)-treated MDA-MB-231 cultures for 48 h and analyzed by flow cytometry (Figure 4). The percentage of the CD11c+ population did not vary significantly among VC-CM-, TPH104-1-CM- and TPH104-5-CM-treated BMDCs (Figure 4B). However, their activation profile was altered as indicated by the levels of MHCII and CD86 (Figure 4C, D). A marked increase is evident for levels of both MHCII and CD86 in BMDCs treated with TPH-1-CM and TPH-5-CM in comparison to VC-CM-treated BMDCs. We observed different activation states of CD11c+ BMDCs such as MHCIIHi, MHCIIlo, CD86Hi and CD86lo populations. Upon incubation with TPH104-1-CM or TPH104-5-CM, MHCIIHi and CD86Hi populations were significantly increased with a corresponding decrease in MHCIIlo and CD86lo populations in CD11c+ BMDCs in comparison to the VC-CM-treated counterpart. Further, incubation of BMDCs with a TLR-4-specific ligand—LPS—shifted the MHCIIlo and CD86lo populations completely (>90%) towards MHCIIHi and CD86Hi (Figure 4E), which was used a quality control experiment to evaluate the maximal activation of DCs. Furthermore, MX-1-CM that was collected from the mitoxantrone (1 µM)-treated MDA-MB-231 culture used as a positive control for immunogenic cell death induction significantly increased the expression of CD11c+ (p < 0.01) compared to BMDCs incubated with VC-CM. In addition, BMDCs treated with MX-1-CM significantly increased MHCII+ (p < 0.05) and CD86+ (p < 0.05) populations in comparison to VC-CM. All these results assert that TPH104-treated (1 and 5 µM) MDA-MB-231 cells release factors that can induce expression of maturation markers such as MHCII and CD86 DCs.
Figure 4. Functional maturation of mouse bone marrow-derived dendritic cells (DCs) (BMDCs) induced by the conditioned media of TPH104-treated MDA-MB-231 cells. (A) Gating strategy used to identify MHCIIlo/Hi and CD86lo/Hi populations in CD11c+ subset of BMDCs. (B) Representative contour plots with their quantitation in the bar graph showing the percentage expression of CD11c+, (C) percentage of MHCIIlo/Hi population and (D) percentage of CD86lo/Hi population, in BMDCs incubated for 24 h in culture media spiked with conditioned media (CM) in the ratio of 7.5:1. The conditioned media were collected from cultures of MDA-MB-231 cells after 48-h treatment with either vehicle (VC-CM), TPH104; 1µM (TPH104-1-CM), TPH104; 5µM (TPH104-5-CM) and/or mitoxantrone; 1µM (MX-1-CM). (E) MHCIIlo/Hi (TOP) and CD86lo/Hi (BOTTOM) populations in CD11c+ subset of BMDCs cultured for 24 h with either VC-CM or LPS (100ng/mL). Data shown in bar graph are mean ± SEM of three or more independent experiments. *, p < 0.05; **, p < 0.01 compared to percentage in DCs treated with VC-CM, Student’s t test.

3.5. MDA-MB-231 Cells Stressed by TPH104 Release Factors to Modulate BMDC Cytokine Expression

The conditioned media, TPH104-1-CM, TPH104-5-CM and MX-1-CM, prepared from MDA-MB-231 cells differentially modulated the cytokine expression of BMDCs. TPH104-5-CM significantly increased the expression of TNF-α (p < 0.01) (Figure 5A), IL-6 (p < 0.05) (Figure 5B) and IL-12A (p < 0.05) (Figure 5D) by 67, 327 and 45%, respectively, compared to VC-CM-incubated BMDCs. The positive control, MX-1-CM, produced a non-significant increase in the mRNA levels of TNF-α (Figure 5A) and IL-6 (Figure 5B) but significantly increased the levels of IL-12A (Figure 5D) (p < 0.01) and IL-12B (p < 0.01) (Figure 5E) by 105 and 166%, compared to cells incubated with the vehicle. The levels of IL-1β did not change significantly in BMDCs incubated with different CM. These data further indicate that THP104- and MX-primed death of MDA-MB-231 cells upregulated a subset of cytokines relevant to tumor immunity.

Figure 5. Effect of culture supernatants from death-primed MDA-MB-231 cells modulate expression of key cytokines in BMDCs. BMDCs were incubated with the indicated CM for 24 h and processed for mRNA expression by qPCR. (A–G) Average fold changes of mRNA levels of TNF-α, IL-6, IL-1β, IL-12A and IL-12B were normalized to β-actin mRNA level. *, p < 0.05; **, p < 0.01; compared to expression in DCs treated with CM from vehicle-treated MDA-MB-231 cells, Student’s t test. n = 4–8 independent experiments.
In Figure 6, we summarize our findings for TPH104-mediated cell death in MDA-MB-231 cells. TPH104 induced a unique, non-apoptotic cell death in MDA-MB-231 cells and increased the expression of immunogenic biomarkers such as ATP and calreticulin. Furthermore, TPH104-mediated death significantly increased TNF-α levels. The TPH104-mediated changes in TNBC can be immunogenic and the factors released by dying cells induce DC maturation and an inflammatory gene expression.

![Figure 6. Schematic representation of TPH104-mediated immunogenic cell death in MDA-MB-231 cells. TPH104 induces a unique, non-apoptotic cell death in TNBC cells and upregulates immunogenic biomarkers such as ATP and calreticulin. Further, TPH104-mediated death prompts these cells to produce TNF-α. The cumulative effect of these manifestations culminates in maturation and activation of inflammatory genes in BMDCs. Activation of DCs can cross-prime cytotoxic T cells to affect antitumor immunity targeting TNBC tumors for destruction.](image)

4. Discussion

The selective targeting of cancer cells, by release of inflammatory cytokines and up-regulation of biomarkers of ICD by dying cancer cells, can increase the killing of cancer cells and decrease tumor cell proliferation by immune cells in the TME [50]. In the present study, the incubation of MDA-MB-231 cells with TPH104 induced the autocrine production of TNF-α from dying MDA-MB-231 cells and increased the expression of the immunogenic markers ATP and CRT.

Cancer cells undergoing ICD mobilize intracellular CRT to the outer leaflet of the plasma membrane to facilitate tumor cell recognition and phagocytosis by DCs and subsequent T cell-mediated elimination of cancer cells [7]. The results of our study indicate that TPH104 induced the translocation of CRT to the plasma membrane of MDA-MB-231 cells in vitro (Figure 2B and S2). The upregulation of CRT by MX has been previously reported, and our results are consistent with those of a previous study [51]. CRT is an endoplasmic reticulum (ER)-resident calcium binding protein that plays a key role in Ca²⁺ homeostasis [52], regulation of nuclear protein transport [53], nuclear steroid receptor signaling [54] and integrin signaling [55] and is a molecular chaperone for the correct folding of polypeptides retained in the ER [54]. The exact mechanism for the translocation of CRT remains to be determined, although published studies indicate that the chemotherapy-mediated ER stress response induces the phosphorylation of eIF2α to facilitate the exocytosis of CRT [17]. Therefore, it is possible that therapies that induce eIF2α phosphorylation, such as inhibitors of the GADD34/PP1 complex, which normally dephosphorylates p(eIF2α) [7], could be useful in the induction of ICD. In addition to CRT externalization, TPH104 (5 µM) significantly increased the levels of extracellular ATP in the culture supernatant of MDA-MB-231 cells (Figure 2A). The active release of ATP by dying cancer cells can sensitize DCs by activating purinergic receptors (P2RX7 and P2RY2) [56].

The induction of apoptosis, [7], γ-irradiation cytotoxicity [7,57] and necroptosis (TNF-α plus ZVADfmk and SMAC mimetics) mobilize plasma membrane CRT and release ATP and HMGB1 [58], producing ICD in cancer cells. Although the detailed modality of cell death induced by TPH104 is described elsewhere (manuscript in submission), the cellular morphological features indicate that it induces non-apoptotic cell death characterized by cell swelling, non-significant nuclear condensation and CRT externalization.
and ATP release. Due to technical limitations, we could not measure HMGB1 levels. Therefore, it is not clear if TPH104 elicits the release of HMGB1 or other alarmins. Furthermore, different cell death programs produce distinct reshuffling processes of the plasma membrane and release intracellular content that plays a crucial role in dying/dead cell-induced immunogenicity [59].

The precise molecular mechanisms that induce secretion of ATP during ICD need to be explored further. As per the current understanding, the apoptotic machinery (caspase3-dependent cleavage of pannexin1 channels for ATP efflux during ICD) [60] and the autophagy competency of cancer [56] are necessary for active secretion of ATP during ICD. This might contradict our findings of ATP release during a non-apoptotic cell death induced by TPH104 in an autophagy incompetent TNBC [61]. However, a caspase/pannexin-1-independent mechanism of ATP release is possible [62]. Cell death induced by TPH104 resembles anoikis—a type of apoptosis induced by a lack of correct cell/ECM attachment that depends on caspase activation and mitochondrial permeabilization [63,64]. Unpublished data from our lab indicate no activation of caspases or annexin staining in TNBC cells treated with TPH104. In view of this, it is unlikely that cells are undergoing anoikis. In addition, during apoptotic cell death, protein synthesis is actively abolished through caspase-mediated destruction of the translational machinery of cells. Contrastingly in TPH104-induced cell death, corpses of MDA-MB-231 still produce TNFα, indicating a non-apoptotic cell death induced by TPH104. A similar phenomenon was reported recently where necrotic corpses of cells can continue to produce protein via an intact ER network even after loss of plasma membrane integrity [65]. The mechanism of cell death induced by TPH104 in MDA-MB-231 is extraordinarily complex and factors driving the ATP release during such a process need a more thorough understanding.

A tumor is a heterogeneous mass of cancer cells, with stromal features such as vasculature, fibroblasts and infiltrating immune cells, which collectively form the TME [66]. The TME is highly variable among tumors and is vital for tumor growth, migration and evasion of the immune response [67]. Furthermore, the TME maintains immunosuppressive conditions by 1) upregulating the expression of immune checkpoint-related molecules, such as the anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) [68], the anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), T cell immunoglobulin and mucin-domain containing-3 (TIM-3) and lymphocyte activation gene-3 (LAG-3) [69]; 2) increasing the population of immuno-regulatory cells; 3) the hypoxic nature of tumors and the presence of hypoxia-driven metabolites, such as lactate, in the TME [70]; and 4) decreasing the efficacy of effector cells by a variety of mechanisms, including inhibition of DC maturation [71]. Therefore, targeting the immunosuppressive TME with ICD inducers can increase adaptive immune priming and improve the efficacy of effector cell killing and cytotoxic therapies.

TPH104-mediated death of MDA-MB-231 cells significantly increased the expression of TNF-α mRNA (Figure 3A) and the release of TNF-α (Figure 3B) into the cell culture supernatant. Necrototic cells can continue to produce cytokines, such as TNF-α, to further optimize necrototic cell death, thereby increasing their immunogenicity [65,72]. In addition, recent reports indicate that activation of the necrototic pathway is associated with inflammatory transcription and cell death simultaneously [72,73]. Furthermore, during certain forms of cell death, even after cells are permeabilized, they can continue to synthesize proteins such as TNFα [65]. Our results are consistent with a previous study indicating that MDA-MB-231 cells produce TNF-α in response to certain chemotherapeutic drugs [34]. In our study, TPH104 increased the expression of TNF-α mRNA, particularly in transformed cells, which could increase the immune response to the tumor in the TME. Our results indicate that DCs exposed to CM from MDA-MB-231 cells incubated with TPH104 (TPH104-CM) induced the maturation of BMDCs (Figure 4). The maturation of DCs can be attributed to TNF-α (Figure 3A, 3B) and other DAMPs in the CM. Earlier studies have shown that the presence of TNF-α during and after ICD increased MHC II expression on APCs and facilitated T cell differentiation and NK cell activation [50,74].
Furthermore, *ex vivo* BMDCs incubated with TNF-α induced their maturation, based on the increased expression of maturation markers, including MHC II and CD86 [75]. Similarly, we observed an increased expression of MHC II and CD86 (Figure 4) in DCs produced by TPH104-CM that could, in part, explain the increase in TNF-α levels in the CM. Furthermore, TPH104 (5 µM) death-primed MDA-MB-231 cells, such as MX-incubated cells, release biomolecules that increase inflammatory gene expression, notably, TNF-α and IL-6, which are downstream of TLRs in DCs.

DCs express both MHC I and II that play a role in the activation of CD8 and CD4 T cells, respectively [11]. DCs phagocytose antigens in the cytosol for cross-presentation of tumor antigens to MHC I, a prerequisite to prime cytotoxic CD8+ T cells [76]. The increase in specific types of mature DCs in the TME has been correlated with favorable outcomes for the stimulation of cytotoxic T cells [77]. It is important to note that multiple subsets of DCs have different effects on tumor immunology [66,78]. Furthermore, antitumor adaptive immune responses are predicted based on the processing of tumor antigens by antigen-presenting cells such as DCs, which, when subjected to appropriate activation signals, migrate to secondary lymphoid tissue, where they prime naïve T cells [76] for targeting tumors bearing those antigens. Therefore, the activation of DCs by extracts of dying MDA-MB-231 cells is a key feature of TPH104-mediated TNBC cytotoxicity that could induce adaptive immune priming against the tumor.

In addition to presenting antigens and co-stimulatory signals being required for the activation of T cells, DCs induce cells to differentiate to interferon (IFN)-γ-producing (Th1 phenotype) or IL-4-producing cells (Th2) [79]. Th1 differentiation is driven by the presence of IL-12 in the microenvironment, where antigen presentation occurs [80,81]. DCs are the major source of IL-12, which is an important stimulatory factor for NK cell activation [82]. Our results indicate that DCs incubated with THPH104-5-CM and MX-1-CM significantly increased the expression of IL-12A and IL12B, respectively (Figure 5). This is a novel and important finding due the fact that IL-12 is a multifunctional cytokine that induces interferon-γ production and stimulates the growth of both T and NK cells, increasing Th1-type helper T cell responses and inhibiting neovascularization [83]. Furthermore, the release of IL-12 by DCs suppresses tumor neovascularization [84]. The efficacy of CM to induce the expression of IL-12 by DCs could be beneficial in facilitating T cell-mediated immunity in the TME and inhibit tumor angiogenesis, a significant feeder of tumor growth and metastasis [85].

The release of inflammatory mediators is important for the synergy between non-apoptotic cell death and immune therapy [2]. Consistent with this concept, our results indicate that TPH104 not only killed MDA-MB-231 cells via a non-apoptotic pathway but also caused ICD, accompanied by the release of the pro-inflammatory mediator TNFα, to increase the adaptive immune response against cancer cells. In addition, the activation of inflammatory gene expression in DCs (Figure 5) can enrich the TME with immune-activating cytokines necessary for efficacious adaptive T cell transfer immunotherapy [49]. Furthermore, the induction of non-apoptotic cell death in TNBCs could be beneficial in overcoming chemotherapy-induced resistance. However, it must be noted that the current presentation of findings has limitations pertaining to the characterization of biomarkers of ICD generated by TNBC in response to TPH104 treatment. The mechanism of TPH104-mediated TNFα production in TNBC cells needs to be investigated in detail. Most importantly, the in vivo efficacy of TPH104-mediated ICD needs to be evaluated. Overall, our results, provided they can be extrapolated to humans, suggest that TPH104 could be a potential candidate for immune adjuvant therapy.

5. Conclusions

In conclusion, TPH104-mediated cell death in TNBC cells showed immunogenic potential that was characterized by the release of ATP and CTR externalization. The efficacy of TPH104 to induce the sustained production of TNF-α specifically by TNBC cells could be used as an adjuvant in cancer chemotherapy as this would decrease the magnitude of
immunosuppression in the TME. The non-apoptotic and immunogenic nature of TNBC cell death produced by TPH104 could be a potential treatment for aggressive TNBC cancers.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/13/8/1954/s1, Figure S1A: Schematic representation of the protocol employed for the collection of conditioned media and ex vivo culture and stimulation of BMDCs. Figure S1B: Percentage of triple positive (CD11c+, MHCII+, CD86+) BMDCs after incubation for 24 h in culture media spiked with conditioned media (CM) in the ratio of 7.5:1. Figure S2. CRT translocate to the cell surface upon incubation with TPH104. Video S1: Time-lapse video, bright field merged with DAPI blue fluorescence shows the morphology of MDA-MB-231 cells during first 30 min of incubation with TPH104 (10 µM).

Author Contributions: Conceptualization, D.B.T., A.K.T.; methodology, D.B.T., S.M., R.A.H., S.K. and A.R.; software, D.B.T. and S.M.; validation, S.S., D.R., S.K. A.R., and A.K.T.; formal analysis, A.K.T.; investigation, S.M. and A.K.T.; resources, A.R. and A.K.T.; data curation, D.B.T. and R.A.H.; writing—original draft preparation, D.B.T. and A.K.T.; writing—review and editing, S.M., R.A.H., D.R., S.S. and A.K.T.; visualization, D.B.T., S.M.; supervision, A.K.T.; project administration, A.K.T.; funding acquisition, A.K.T. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the Susan G. Komen Breast Cancer Foundation Funding Agency under Grant CCR18548498 to A.K.T.; National Institute of Health (NIH)/National Cancer Institute under Grant R21CA202176 to D.R.

Institutional Review Board Statement: Ethical review and approval were waived for this study, as no studies were performed in the live animals. The samples were used from the sacrificed mice obtained from the other University of Toledo’s Institutional Review Board ethically approved protocols.

Informed Consent Statement: Not applicable.

Data Availability Statement: Any raw data presented in this study is available on request to the corresponding author. Supporting information is available in the attached supplementary files.

Acknowledgments: The authors thank Charles R. Ashby, Jr., St. John’s University, Queens, NY, for his critical editing of this manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wu, J.; Waxman, D.J. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 2018, 419, 210-221, doi:10.1016/j.canlet.2018.01.050.
2. Apetoh, L.; Tesniere, A.; Ghiringhelli, F.; Kroemer, G.; Zitvogel, L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008, 68, 4026-4030, doi:10.1158/0008-5472.CAN-08-0427.
3. Fucikova, J.; Kralikova, P.; Fialova, A.; Brtnicky, T.; Rob, L.; Bartunkova, J.; Spisek, R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011, 71, 4821-4833, doi:10.1158/0008-5472.CAN-11-0950.
4. Galluzzi, L.; Senovilla, L.; Zitvogel, L.; Kroemer, G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012, 11, 215-233, doi:10.1038/nrd3626.
5. Garg, A.D.; More, S.; Rufo, N.; Mece, O.; Sassano, M.L.; Agostinis, P.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017, 6, e1386829, doi:10.1080/2162402X.2017.1386829.
6. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Ivata, H.; Dieras, V.; Hegh, R.; Im, S.A.; Shaw Wright, G., et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018, 379, 2108-2121, doi:10.1056/NEJMoa1809615.
7. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G.M.; Apetoh, L.; Perfettini, J.L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13, 54-61, doi:10.1038/nm1523.
8. Kroemer, G.; Galluzzi, L.; Kepp, O.; Zitvogel, L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31, 51-72, doi:10.1146/annurev-immunol-032712-100008.
9. Galluzzi, L.; Buque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. Immunogenic cell death in cancer and infectious disease. *Nat Rev Immunol* 2017, 17, 97-111, doi:10.1038/nri.2016.107.

10. Bajor, A.; Tischer, S.; Figueiredo, C.; Wittmann, M.; Immenschuh, S.; Blaszczyk, R.; Eiz-Vesper, B. Modulatory role of calreticulin as chaperone for dendritic cell-based immunotherapy. *Clin Exp Immunol* 2011, 165, 220-234, doi:10.1111/j.1365-2249.2011.04423.x.

11. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. *Nature* 1998, 392, 245-252, doi:10.1038/32588.

12. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoeediting: integrating immunity’s roles in cancer suppression and promotion. *Science* 2011, 331, 1565-1570, doi:10.1126/science.1203486.

13. Saxena, M.; Bhandari, N. Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. *Trends Cancer* 2018, 4, 119-137, doi:10.1016/j.trecan.2017.12.007.

14. Panaretakis, T.; Joza, N.; Modjtahedi, N.; Tesniere, A.; Vitale, I.; Dürchsclag, M.; Fimia, G.M.; Kepp, O.; Piccinni, M.; Froehlich, K.U., et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. *Cell Death Differ* 2008, 15, 1499-1509, doi:10.1038/cdd.2008.67.

15. Johnson, S.; Michalak, M.; Opas, M.; Eggleton, P. The ins and outs of calreticulin: from the ER lumen to the extracellular space. *Trends Cell Biol* 2001, 11, 122-129, doi:10.1016/s0962-8924(01)01926-2.

16. Inaba, K.; Turley, S.; Yamaide, F.; Iyoda, T.; Mahnke, K.; Inaba, M.; Pack, M.; Subklewe, M.; Sauter, B.; Sheff, D., et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex II products of dendritic cells. *J Exp Med* 1998, 188, 2163-2173, doi:10.1084/jem.188.11.2163.

17. Tufi, R.; Panaretakis, T.; Bianchi, K.; Cioiello, A.; Fazi, B.; Di Sano, F.; Tesniere, A.; Kepp, O.; Paterlini-Brechet, P.; Zitvogel, L., et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. *Cell Death Differ* 2008, 15, 274-282, doi:10.1038/sj.cdd.4402275.

18. Garg, A.D.; Krysko, D.V.; Verfaillie, T.; Kaczmarek, A.; Firczuk, M.; Mathieu, C.; Roebroek, A.J., et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. *EMBO J* 2012, 31, 1062-1079, doi:10.1038/emboj.2011.497.

19. Sims, G.P.; Rowe, D.C.; Riedtijk, S.T.; Herbst, R.; Coyle, A.J. HMGB1 and RAGE in inflammation and cancer. *Annu Rev Immunol* 2010, 28, 367-388, doi:10.1146/annurev.immunol.021908.132603.

20. Bauer, D.; Mazzio, E.; Soliman, K.F. Whole transcriptomic analysis of apigenin on TNF-α immuno-activated MDA-MB-231 breast cancer cells. *Cancer Genomics-Proteomics* 2019, 16, 421-431.

21. Hwang, I.; Nguyen, N. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. *Arch Pharm Res* 2015, 38, 1415-1433, doi:10.1007/s12272-015-0566-y.

22. Töpfér, K.; Kempe, S.; Müller, N.; Schmitz, M.; Bachmann, M.; Cartellieri, M.; Schackert, G.; Temme, A. Tumor evasion from T cell surveillance. *J Biomed Biotechnol* 2011, 2011, 918471, doi:10.1155/2011/918471.

23. Li, Z.; Qiu, Y.; Lu, W.; Jiang, Y.; Yang, J. Immunotherapeutic interventions of Triple Negative Breast Cancer. *J Transl Med* 2018, 16, 147, doi:10.1186/s12976-018-1514-7.

24. Wein, L.; Savas, P.; Luen, S.J.; Virassamy, B.; Salgado, R.; Loi, S. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. *Front Oncol* 2017, 7, 156, doi:10.3389/fonc.2017.00156.

25. Lee, H.J.; Park, I.A.; Song, I.H.; Shin, S.J.; Kim, J.Y.; Yu, J.H.; Gong, G. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. *J Clin Pathol* 2016, 69, 422-430, doi:10.1136/jclinpath-2015-203089.

26. Lee, H.; Lee, H.J.; Song, I.H.; Bang, W.S.; Heo, S.H.; Gong, G.; Park, I.A. CD11c-Positive Dendritic Cells in Triple-negative Breast Cancer. *In Vivo* 2018, 32, 1561-1569, doi:10.21873/invivo.11415.

27. Gosavi, R.A.; Salwe, S.; Mukherjee, S.; Dahake, R.; Kothari, S.; Patel, V.; Chowdhary, A.; Deshmukh, R.A. Optimization of Ex Vivo Murine Bone Marrow Derived Immature Dendritic Cells: A Comparative Analysis of Flask Culture Method and Mouse CD11c Positive Selection Kit Method. *Bone Marrow Res* 2018, 3495086, doi:10.1155/2018/3495086.

28. Sedger, L.M.; McDermott, M.F. TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. *Cytokine Growth Factor Rev* 2014, 25, 453-472, doi:10.1016/j.cytogfr.2014.07.016.

29. Josephs, S.F.; Ichim, T.E.; Prince, S.M.; Kesari, S.; Marincola, F.M.; Escobedo, A.R.; Jafri, A. Unleashing endogenous TNF-alpha as a cancer immunotherapeutic. *J Transl Med* 2018, 16, 242, doi:10.1186/s12976-018-1611-7.

30. de Almagro, M.C.; Goncharov, T.; Newton, K.; Vucic, D. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. *Cell Death Dis* 2015, 6, e1800, doi:10.1038/cddis.2015.158.

31. Desmedt, C.; Di Leo, A.; de Azambuja, E.; Larsimont, D.; Haibe-Kains, B.; Selleslag, J.; Delaloge, S.; Duhem, C.; Kains, J.P.; Carly, B., et al. Multifactorial approach to predicting resistance to anthracyclines. *J Clin Oncol* 2011, 29, 1578-1586, doi:10.1200/JCO.2010.31.2231.

32. Gomez-Miragaya, J.; Palafax, M.; Pare, L.; Yoldi, G.; Ferrer, I.; Vila, S.; Galvan, P.; Pellegrini, P.; Perez-Montoyo, H.; Igea, A., et al. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. *Stem Cell Reports* 2017, 8, 1392-1407, doi:10.1016/j.stemcr.2017.03.026.

33. Su, Z.; Yang, Z.; Xie, L.; DeWitt, J.P.; Chen, Y. Cancer therapy in the necroptosis era. *Cell Death Differ* 2016, 23, 748-756, doi:10.1038/cdd.2016.8.
34. Christofferson, D.E.; Li, Y.; Hitomi, J.; Zhou, W.; Upperman, C.; Zhu, H.; Gerber, S.A.; Gygi, S.; Yuan, J. A novel role for RIP1 kinase in mediating TNFalpha production. *Cell Death Dis* 2012, 3, e320, doi:10.1038/cddis.2012.64.

35. Dubar, G.; Azria, E.; Tesniere, A.; Dupont, H.; Le Ray, C.; Baugnon, T.; Matheron, S.; Luton, D.; Richard, J.C.; Launay, O., et al. French experience of 2009 A/H1N1v influenza in pregnant women. *PLoS One* 2010, 5, doi:10.1371/journal.pone.0013112.

36. Zhao, X.; Yang, K.; Zhao, R.; Ji, T.; Wang, X.; Yang, X.; Cheng, K.; Liu, S.; Hao, J., et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. *Biomaterials* 2016, 102, 187-197, doi:10.1016/j.biomaterials.2016.06.032.

37. Kawano, M.; Tanaka, K.; Itonaga, I.; Iwasaki, T.; Miyazaki, M.; Ikeda, S.; Tsumura, H. Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. *OncoL Lett* 2016, 11, 2169-2175, doi:10.3892/ol.2016.4175.

38. Menger, L.; Vacchelli, E.; Adjemian, S.; Martins, I.; Ma, Y.; Shen, S.; Yamazaki, T.; Sukkurwala, A.Q.; Michaud, M.; Mignot, G., et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. *Sci Transl Med* 2012, 4, 143ra199, doi:10.1126/scitranslmed.3003807.

39. Dudek-Peric, A.M.; Ferreira, G.B.; Muchowicz, A.; Wouters, J.; Prada, N.; Martin, S.; Kiviluoto, S.; Winiarska, M.; Boon, L.; Mathieu, C., et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. *Cancer Res* 2015, 75, 1603-1614, doi:10.1158/0008-5472.CAN-14-2089.

40. Song, K.H.; Jung, S.Y.; Kang, S.M.; Kim, M.H.; Ahn, J.; Hwang, S.G.; Lee, J.H.; Lim, D.S.; Nam, S.Y.; Song, J.Y. Induction of immunogenic cell death by radiation-upregulated karyopherin alpha 2 in vitro. *Eur J Cell Biol* 2016, 95, 219-227, doi:10.1016/j.ejcb.2016.04.002.

41. Tiwari, A.K.; Karthikeyan, C.; Nyinawabera, A. Necroptosis inducers or autophagy inhibitors or a combination hereof. WO201920021A1, 2019.

42. Amawi, H.; Hussein, N.; Boddu, S.H.S.; Karthikeyan, C.; Williams, F.E.; Ashby, C.R., Jr.; Raman, D.; Trivedi, P.; Tiwari, A.K. Novel Thienopyrimidine Derivative, RP-010, Induces beta-Catenin Fragmentation and Is Efficacious against Prostate Cancer Cells. *Cancers (Basel)* 2019, 11, doi:10.3390/cancers1105071.

43. Al-Oudat, B.A.; Ramapuram, H.; Malla, S.; Audat, S.A.; Hussein, N.; Len, J.M.; Kumari, S.; Bedi, M.F.; Ashby, C.R., Jr.; Tiwari, A.K. Novel Chrysins-De-Allyl PAC-1 Hybrid Analogues as Anticancer Compounds: Design, Synthesis, and Biological Evaluation. *Molecules* 2020, 25, 3063.

44. Aaes, T.L.; Kazmzarek, A.; Delvaeye, T.; De Craene, B.; De Koker, S.; Heyndrickx, L.; Delrue, I.; Taminau, J.; Wiernicki, B.; De Groote, P., et al. Vaccination with Necrototic Cancer Cells Induces Efficient Anti-tumor Immunity. *Cell Rep* 2016, 15, 274-287, doi:10.1016/j.celrep.2016.03.037.

45. Diwakar, B.T.; Yoast, R.; Nettleford, S.; Qian, F.; Lee, T.J.; Berry, S.; Huffnagle, I.; Rossi, R.M.; Trebak, M.; Paulson, R.F., et al. Crtb2 receptor signaling down-regulates lipopolysaccharide-induced NF-kappaB activation in murine macrophages via changes in intracellular calcium. *FASEB J* 2019, doi:10.1096/fj.201802608R, doi:10.1096/fj.201802608R.

46. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001, 25, 402-408, doi:10.1016/meth.2001.12.062.

47. Majno, G.; Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* 1995, 146, 3-15.

48. Trompetta, E.S.; Ebersold, M.; Garrett, W.; Pypaert, M.; Mellman, I. Activation of lysosomal function during dendritic cell maturation. *Science* 2003, 299, 1400-1403, doi:10.1126/science.1080106.

49. Marigo, I.; Zilio, S.; Desantis, G.; Mlecnik, B.; Agnellini, A.H.; Ugel, S.; Sassu, M.S.; Qualls, J.E.; Kratochvill, F.; Zanovello, P., et al. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. *Cancer Cell* 2016, 30, 651, doi:10.1016/j.ccell.2016.09.009.

50. Showalter, A.; Limaye, A.; Oyer, J.L.; Igarashi, R.; Kittipatarin, C.; Copik, A.J.; Khaled, A.R. Cytokines in immunogenic cell death: Applications for cancer immunotherapy. *Cytokine* 2017, 97, 123-132, doi:10.1016/j.cyto.2017.05.024.

51. Hodge, J.W.; Garnett, C.T.; Farsaci, B.; Palena, C.; Tsang, K.Y.; Ferrone, S.; Gameiro, S.R. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. *Int J Cancer* 2013, 133, 624-636, doi:10.1002/ijc.28070.

52. Groenendyk, J.; Lynch, J.; Michalak, M. Calreticulin, Ca2+, and calcineurin - signaling from the endoplasmic reticulum. *Mol Cells* 2004, 17, 383-389.

53. Holaska, J.M.; Black, B.E.; Rastinejad, F.; Paschal, B.M. Ca2+-dependent nuclear export mediated by calreticulin. *Mol Cell Biol* 2002, 22, 6286-6297, doi:10.1128/mcb.22.17.6286-6297.2002.

54. Meldolesi, J.; Krause, K.H.; Michalak, M. Calreticulin: how many functions in how many cellular compartments? *Compo* April 1996, *Cell Calcium* 1996, 20, 83-86, doi:10.1006/sic1-43-416(96)0053-6.

55. Coppolino, M.G.; Woodside, M.J.; Demaurex, N.; Grinstein, S.; St-Arnaud, R.; Dedhar, S. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. *Nature* 1997, 386, 843-847, doi:10.1038/386843a0.

56. Michaud, M.; Martins, I.; Sukkurwala, A.Q.; Adjemian, S.; Ma, Y.; Pellegratti, P.; Shen, S.; Kepp, O.; Scoazec, M.; Mignot, G., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. *Science* 2011, 334, 1573-1577, doi:10.1126/science.1208347.

57. Obeid, M.; Panaretakis, T.; Joza, N.; Tufi, R.; Tesniere, A.; van Endert, P.; Zitvogel, L.; Kroemer, G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. *Cell Death Differ* 2007, 14, 1848-1850, doi:10.1038/sj.cdd.4402201.
58. Yang, H.; Ma, Y.; Chen, G.; Zhou, H.; Yamazaki, T.; Klein, C.; Pietrocola, F.; Vacchelli, E.; Souquere, S.; Sauvat, A., et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. *Oncoimmunology* 2016, 5, e1149673, doi:10.1080/2162402X.2016.1149673.

59. Zhang, Y.; Chen, X.; Gueydan, C.; Han, J. Plasma membrane changes during programmed cell deaths. *Cell Res* 2018, 28, 9-21, doi:10.1038/cr.2017.133.

60. Cariello, N.F.; Koehavong, P.; Kat, A.G.; Thilly, W.G. Molecular analysis of complex human cell populations: mutational spectra of MNNG and ICR-191. *Mutat Res* 1990, 231, 165-176, doi:10.1007/1027-5107(90)90023-w.

61. Li, Z.L.; Zhang, H.L.; Huang, Y.; Huang, J.H.; Sun, P.; Zhou, N.N.; Chen, Y.H.; Mai, J.; Wang, Y.; Yu, Y., et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. *Nat Commun* 2020, 11, 3065, doi:10.1038/s41467-020-17395-y.

62. Boyd-Tressler, A.; Penuela, S.; Laird, D.W.; Dubyak, G.R. Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism. *J Biol Chem* 2014, 289, 27246-27263, doi:10.1074/jbc.M114.590240.

63. Gilmore, A.P. Anoikis. *Cell Death Differ* 2005, 12 Suppl 2, 1473-1477, doi:10.1038/sj.cdd.4401723.

64. Tajbakhsh, A.; Rivandi, M.; Abединi, S.; Pasdar, A.; Sahebkar, A. Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review. *Crit Rev Oncol Hematol* 2019, 140, 17-27, doi:10.1016/j.critrevonc.2019.05.009.

65. Orozco, S.L.; Daniels, B.P.; Yatim, N.; Messmer, M.N.; Quarto, G.; Chen-Harris, H.; Cullen, S.P.; Snyder, A.G.; Ralli-Jain, P.; Frase, S. RIPK3 activation leads to cytokine synthesis that continues after loss of cell membrane integrity. *Cell reports* 2019, 28, 2275-2287, e2275.

66. Demoulin, S.; Herfs, M.; Delvenne, P.; Hubert, P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. *J Leukoc Biol* 2019, 133, 343-352, doi:10.1189/jlb.0812397.

67. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. *Nat Rev Cancer* 2005, 5, 263-274, doi:10.1038/nrc1586.

68. Sun, C.; Mezzadra, R.; Schumacher, T.N. Regulation and Function of the PD-L1 Checkpoint. *Immunity* 2018, 48, 434-452, doi:10.1016/j.immuni.2018.03.014.

69. Qin, S.; Xu, L.; Yi, M.; Yu, S.; Wu, K.; Luo, S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. *Mol Cancer* 2019, 18, 155, doi:10.1186/s12943-019-1091-2.

70. Li, Y.; Patel, S.P.; Roszik, J.; Qin, Y. Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy. *Front Immunol* 2018, 9, 1591, doi:10.3389/fimmu.2018.01591.

71. Beatty, G.L.; Gladney, W.L. Immune escape mechanisms as a guide for cancer immunotherapy. *Clin Cancer Res* 2015, 21, 687-692, doi:10.1158/1078-0432.CCR-14-1860.

72. Snyder, A.G.; Hubbard, N.W.; Messmer, M.N.; Kofman, S.B.; Hagan, C.E.; Orozco, S.L.; Chiang, K.; Daniels, B.P.; Baker, D.; Oberst, A. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. *Sci Immunol* 2019, 4, doi:10.1126/sciimmunol.aaw004.

73. Yatim, N.; Justforges-Saklani, H.; Orozco, S.; Schulz, O.; Barreira da Silva, R.; Reis e Sousa, C.; Green, D.R.; Oberst, A.; Albert, M.L. RIPK1 and NF-kB signaling in dying cells determines cross-priming of CD8+ T cells. *Science* 2015, 350, 328-334, doi:10.1126/science.aad0395.

74. San, W.; Peska, S.; Jorgin, R.G.; Lyu, Y.L.; Tsai, Y.C.; Liu, L.F. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. *PloS One* 2012, 7, e23542, doi:10.1371/journal.pone.0023542.

75. Brunner, C.; Seiderer, J.; Schlamp, A.; Bidlingmaier, M.; Eigler, A.; Haimerl, W.; Lehr, H.A.; Krieg, A.M.; Hartmann, G.; Endres, S. Enhanced dendritic cell maturation by TNF-alpha or cytokine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. *J Immunol* 2000, 165, 6278-6286, doi:10.4049/jimmunol.165.11.6278.

76. den Haan, J.M.; Lehar, S.M.; Bevan, M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. *Exp Med* 2000, 192, 1685-1696, doi:10.1084/jem.192.12.1685.

77. Broz, M.; Binnewies, M.; Boldajipour, B.; Nelson, A.E.; Pollack, J.L.; Erle, D.J.; Barczak, A.; Rosenblum, M.D.; Daud, A.; Barber, D.L., et al. Dissecting the tumor milieu in human cancer reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* 2014, 26, 638-652, doi:10.1016/j.ccell.2014.09.007.

78. Chen, W.; Liang, X.; Peterson, A.J.; Munn, D.H.; Blazar, B.R. The indoleamine 2,3-dioxygenase pathway is essential for antitumor immunity. *Science* 2008, 181, 5396-5404, doi:10.4049/jimmunol.181.5.5396.

79. den Haan, J.M.; Bevan, M.J. A novel helper role for CD4 T cells. *Proc. Natl. Acad. Sci. U.S.A.* 2000, 97, 12950-12952, doi:10.1073/pnas.97.24.12950.

80. Gately, M.K.; Renzetti, L.M.; Magram, J.; Stern, A.S.; Adorini, L.; Gubler, U.; Presky, D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. *Annu Rev Immunol* 1998, 16, 495-521, doi:10.1146/annurev.immunol.16.1.495.

81. Murphy, K.M.; Reiner, S.L. The lineage decisions of helper T cells. *Nat Rev Immunol* 2002, 2, 933-944, doi:10.1038/nri954.

82. Martin-Fontecha, A.; Thomesen, L.L.; Brett, S.; Gerard, C.; Lipp, M.; Lanzavecchia, A.; Sallusto, F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. *Nat Immunol* 2004, 5, 1260-1265, doi:10.1038/ni1138.
83. Sgadari, C.; Angiolillo, A.L.; Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. *Blood* **1996**, *87*, 3877-3882.

84. Curiel, T.J.; Cheng, P.; Mottram, P.; Alvarez, X.; Moons, L.; Evdemon-Hogan, M.; Wei, S.; Zou, L.; Kryczek, I.; Hoyle, G., et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. *Cancer Res* **2004**, *64*, 5535-5538, doi:10.1158/0008-5472.CAN-04-1272.

85. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. *Nature* **2000**, *407*, 249-257, doi:10.1038/35025220.